Physician profile
Ana W Pacis
NPI 1194323121
$6,760.21
in general payments reported to CMS, 2019-2025
30 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,099 · 2022: $1,698 · 2023: $1,670 · 2024: $146 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,500.47 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,031.21 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $488.85 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.08 | 2021-2022 | |
| Lilly USA, LLC | $398.90 | 2021-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $362.57 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $297.39 | 2021-2023 | |
| Amarin Pharma, INC. | $251.94 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $245.21 | 2021 | |
| Sanofi-Aventis U.S. LLC | $190.67 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.39 | 2022-2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $158.11 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $154.17 | 2021-2022 | |
| Amgen INC. | $150.89 | 2021-2023 | Repatha, Otezla |
| Madrigal Pharmaceuticals | $118.01 | 2025 | Rezdiffra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $101.13 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.64 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $90.11 | 2022 | |
| Dexcom, INC. | $69.89 | 2022-2023 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $61.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.61 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $57.40 | 2021-2023 | Austedo |
| Scilex Pharmaceuticals INC. | $44.90 | 2023-2024 | Ztlido, Elyxyb |
| Janssen Pharmaceuticals, INC | $44.39 | 2021 | |
| Xeris Pharmaceuticals, INC. | $41.88 | 2021-2023 | Gvoke Hypopen |
| Medtronic, INC. | $29.75 | 2025 | Symplicity G3 |
| Exact Sciences Corporation | $24.89 | 2023 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $24.06 | 2021 | |
| Genentech USA, INC. | $22.72 | 2021 | |
| Astellas Pharma US INC | $20.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Pacis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.